Using computers to identify non-compliant people at increased risk of osteoporotic fractures in general practice: a cross-sectional study
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
National guidelines recommend bisphosphonates for secondary prevention of osteoporotic fractures; however, poor compliance may result in sub-optimal prevention.
This study reports the feasibility of using GP electronic records to identify poorly compliant post-menopausal women who may be at increased risk of fragility fractures.
Cross-sectional study of general practice computer records.
Women over 45 years, registered in 29 practices across England with a total population of approximately 200,000.
MIQUEST (Morbidity Information Query and Export Syntax) a data extraction application was used to extract prescription, diagnostic data and probable fragility fractures (hip, vertebral, wrist). All women >45 years who received a first prescription for a weekly bisphosphonate (alendronate or risedronate) at least a year before data extraction were identified. Each record was examined to determine the number of days of prescribed treatment.
Of 97992 registered women, 44% (42734) were >45 years. Prevalence of likely fragility fractures in women over 45 was 5.1% (2195/42734). 3.0% (1286/42734, mean age 72 years) received a prescription for a bisphosphonate in the 360 day period prior to data extraction with a median duration of treatment of 267 days. 45% (584/1286) received prescriptions covering >288/360 days (Medicine Possession Ratio >80%); 13% (161/1286) collected prescriptions covering >360 days. In those prescribed bisphosphonates, 23% (294/1286) had a likely fragility fracture.
Women >45 years with probable fragility fractures are more likely to be prescribed bisphosphonates, though less than half will be actually taking them as prescribed. GPs should use computer technology to identify poorly compliant patients who are unnecessarily at risk of fracture.
- Black, DM, Cummings, SR, Karpf, DB, Cauley, JA, Thompson, DE, Nevitt, MC, Bauer, DC, Genant, HK, Haskell, WL, Marcus, R, Ott, SM, Torner, JC, Quandt, SA, Reiss, TF, Ensrud, KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: pp. 1535-1541 CrossRef
- Harris, ST, Watts, NB, Genant, HK, McKeever, CD, Hangartner, T, Keller, M, Chesnut, CH, Brown, J, Eriksen, EF, Hoseyni, MS, Axelrod, DW, Miller, PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomised controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282: pp. 1344-1352 CrossRef
- Delmas, PD, Ensrud, KE, Adachi, JD, Harper, KD, Sarkar, S, Gennari, C, Reginster, JY, Pols, HA, Recker, RR, Harris, ST, Wu, W, Genant, HK, Black, DM, Eastell, R (2002) Mulitple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomised clinical trial. J Clin Endocrinol Metab 87: pp. 3609-3617 CrossRef
- Chesnut, CH, Skag, A, Christiansen, C, Recker, R, Stakkestad, JA, Hoiseth, A, Felsenberg, D, Huss, H, Gilbride, J, Schimmer, RC, Delmas, PD (2004) Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19: pp. 1241-1249 CrossRef
- Recker, RR, Gallagher, R, MacCosbe, PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80: pp. 856-861 CrossRef
- McCombs, JS, Thiebaud, P, McLaughlin-Miley, C, Shi, J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48: pp. 271-287 CrossRef
- Johnell, O, Kanis, JA, Oden, A, Johansson, H, Laet, C, Delmas, P, Eisman, JA, Fujiwara, S, Kroger, H, Mellstrom, D, Meunier, PJ, Melton, LJ, O’Neill, T, Pols, H, Reeve, J, Silman, A, Tenenhouse, A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20: pp. 1185-1194 CrossRef
- Caro, JJ, Ishak, KJ, Huybrechts, KF, Raggio, G, Naujoks, C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15: pp. 1003-1008 CrossRef
- Pols, HA, Felsenberg, D, Hanley, DA, Stepan, J, Munoz-Torres, M, Wilkin, TJ, Qin-sheng, G, Galich, AM, Vandormael, K, Yates, AJ, Stych, B (1999) Multinational, placebo-controlled, randomised trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 9: pp. 461-468 CrossRef
- Huybrechts KF, Ishak KJ, Caro JJ (2005) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone Dec 1 [Epub ahead of print]
- National Institute for Clinical Excellence (NICE) Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. London; NICE Technology Appraisal 87, 2005
- Lusignan, S, Chan, T, Wood, O, Hague, N, Valentin, T, Vlymen, J (2005) Quality and variability of osteoporosis data in general practice computer records: implications for disease registers. Public Health 119: pp. 771-780 CrossRef
- Mitchell, E, Sullivan, F (2001) A descriptive feast but an evaluative famine: systematic review of published articles on primary care computing during 1980–1997. BMJ 322: pp. 279-282 CrossRef
- Lusignan, S, Valentin, T, Chan, T, Hague, N, Wood, O, Vlymen, J, Dhoul, N (2004) Problems with primary care data quality: osteoporosis as an exemplar. Inform. Prim Care 12: pp. 147-156
- Lusignan, S, Chan, T, Stevens, P, O’Donoghue, D, Hague, N, Dzregah, B, Vlymen, J, Walker, M, Hilton, S (2005) Identifying patients with chronic kidney disease from general practice computer records. Fam Pract 22: pp. 234-241 CrossRef
- Lusignan, S, Hague, N, Brown, A, Majeed, A (2004) An educational intervention to improve data recording in the management of ischaemic heart disease in primary care. J Public Health (Oxf) 26: pp. 34-37 CrossRef
- Lusignan, S, Chan, T, Wells, S, Cooper, A, Harvey, M, Brew, S, Wright, M (2003) Can patients with osteoporosis, who should benefit from implementation of the national service framework for older people, be identified from general practice computer records? A pilot study that illustrates the variability of computerised medical records and problems with searching them. Public Health 117: pp. 438-445 CrossRef
- Vlymen, J, Lusignan, S, Hague, N, Chan, T, Dzregah, B (2005) Ensuring the Quality of Aggregated General Practice Data: Lessons from the Primary Care Data Quality Programme (PCDQ). Stud Health Technol Inform 116: pp. 1010-1015
- van Vlymen J, de Lusignan S. A system of metadata to control the process of query, aggregating, cleaning and analysing large datasets of primary care data. Accepted for publication. Informatics in Primary Care September 2005
- Clinical Information Consultancy. MIQUEST (Morbidity Information Query and Export Syntax). URL: http://www.clininfo.co.uk/main/miquest.htm
- NHS Public Health Network. Directly age-standardised rates. Downloaded from: http://www.avon.nhs.uk/phnet/methods/directly_age_standardised_rates.htm. Accessed 3rd July 2005
- National Statistics. Population Trends 2003; 113 (Autumn): 45 (Table 1.4). Downloaded from: http://www.statistics.gov.uk/downloads/theme_population/PT113.pdf. Accessed 3rd July 2005
- Sanders, KM, Nicholson, GC, Watts, JJ, Pasco, JA, Henry, MJ, Kotowicz, MA, Seeman, E (2006) Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective?. Bone 38: pp. 694-700 CrossRef
- Krueger, KP, Felkey, BG, Berger, BA (2003) Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. J Am Pharm Assoc 43: pp. 668-678 CrossRef
- Richter, A, Anton, SE, Koch, P, Dennett, SL (2003) The impact of reducing dose frequency on health outcomes. Clin Ther 25: pp. 2307-2335 CrossRef
- Cummings, SR, Melton, LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359: pp. 1761-1767 CrossRef
- Holt, G, Khaw, KT, Reid, DM, Compston, JE, Bhalla, A, Woolf, AD, Crabtree, NJ, Dalzell, N, Wardley-Smith, B, Lunt, M, Reeve, J (2002) Prevalence of osteoporotic bone mineral density at the hip in Britain differs substantially from the US over 50 years of age: implications for clinical densitometry. Br J Radiol 75: pp. 736-742
- Vik, SA, Maxwell, CJ, Hanley, DA (2005) Treatment of osteoporosis in an older home care population. BMC Musculoskelet Disord 6: pp. 7 CrossRef
- Using computers to identify non-compliant people at increased risk of osteoporotic fractures in general practice: a cross-sectional study
Volume 17, Issue 12 , pp 1808-1814
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Medical records systems
- Patient compliance
- Treatment refusal
- Industry Sectors